[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Stakeholder](https://github.com/mm80843/T3.5/tree/pages/docs/Stakeholder/index.md) >> Individual ID:PBN__Stakeholder_4250 

# __Medical research institutions__

## Risks that can be mitigated by this stakeholder

* [Absence of specific treatment or vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5048.md)
* [Acceleration of testing kit development using ai](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5229.md)
* [Ai predictive models may have accuracy limitations and may not always provide accurate predictions for severe cases of covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6538.md)
* [Application of ai in medical research and social context during pandemic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6546.md)
* [Deployment of ai to diagnose covid-19 symptoms and pneumonia](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6592.md)
* [Deposition of droplets in respiratory system](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6673.md)
* [High mortality rates of known coronaviruses mers-cov, sars-cov](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6680.md)
* [Inaccurate identification of specific diseases due to biomarkers not being specific to a given disease, leading to misdiagnosis and ineffective containment measures.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6782.md)
* [Inadequate clinical understanding of covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7113.md)
* [Inadequate data collection and efforts may lead to ineffective management of contagious diseases.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7130.md)
* [Inadequate evaluation of drugs for covid-19 therapy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7949.md)
* [Inadequate testing methods for contagious diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10408.md)
* [Inadequate utilization of urine proteomics for disease biomarkers](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10413.md)
* [Insufficient testing and approval of medical inventions for disease prevention may lead to ineffective or unsafe products being used in the market](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10442.md)
* [Lack of conclusive evidence for the effectiveness of shl oral liquid against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13766.md)
* [Need for treatments and approaches to combat specific viral proteins](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14263.md)
* [Use of improvised breathing aids and devices, such as snood-type masks, without proper filtration and purification systems may lead to inadequate protection against airborne viruses.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18669.md)

## This Stakeholder belongs to this Stakeholder Group

* [Research organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_0.md)

## This Stakeholder belongs to this Stakeholder Subgroup

* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_5.md)

